Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 3/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698446 | 0.93 | DRD2 (0.61) | DRD2HTR2AHTR2CHTR1AADRA1A | |
| SCHEMBL7800271 | 0.87 | MEN1 (0.57) | DRD2HTR1AADRA1AADRA1BADRA1D | |
| SCHEMBL13648739 | 0.86 | DRD2 (0.65) | DRD2HTR2AHTR2CHTR1AADRA1A | |
| SCHEMBL12962061 | 0.85 | HTR1A (0.54) | DRD2HTR2AHTR2CHTR1AADRA1A | |
| Ammonia Solution, Strong SCHEMBL2320933 | 0.85 | DRD2 (0.64) | DRD2HTR2AHTR2CHTR1AADRA1A | |
| SCHEMBL7782280 | 0.83 | ADRA1A (0.61) | DRD2HTR1AADRA1AADRA1BADRA1D | |
| SCHEMBL4478827 | 0.81 | HTR1A (0.51) | DRD2HTR2AHTR2CHTR1AADRA1A | |
| SCHEMBL12962322 | 0.81 | HTR1A (0.59) | DRD2HTR2AHTR2CHTR1AADRA1A | |
| SCHEMBL1779199 | 0.80 | DRD2 (0.62) | DRD2HTR2AHTR2CHTR1AADRA1A | |
| SCHEMBL13698459 | 0.80 | DRD2 (0.60) | DRD2ADRA1AADRA1BADRA1DDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010014680-A1 | 1,4-piperazine derivatives | WYETH | 2001-08-16 | — | — | US | claimed |
| US-6255302-B1 | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS | AMERICAN HOME PRODUCTS CORPORATION | 2001-07-03 | — | — | US | claimed |
| US-20010014680-A1 | 1,4-piperazine derivatives | WYETH | 2001-08-16 | — | — | US | disclosed |
| US-6255302-B1 | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS | AMERICAN HOME PRODUCTS CORPORATION | 2001-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014680-A1 | 1,4-piperazine derivatives | ADH1A, ADH1C, SNCA | DRD2 12/4885HTR2A 53/4885HTR2C 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.